Need help?

Will you send me the results directly?

Please review our patient information leaflet

Patient info leaflet

Do I need to go through my GP to get a test?

Please review our patient information leaflet

Patient info leaflet

Can RGCC test for BRAF drugs?

Yes. Onconomics and Onconomics Plus tests can be used for Ras-Raf-MEK-Erk, dabrafenib, vemurafenib, c-Jun, C-Fos, trametinib and sorafenib.

Can the Oncotrace test differentiate between benign and malignant tumour cells?

Yes. The Oncotrace test provides information about the presence of circulating tumour cells, their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.

I have a patient whose specific tumour appears to have resisting populations because of the overexpression of the MDR1 gene. This can be reversed by the use of inhibitors of ABG2 pumps. What do I do?

In this case, a patient could proceed with ketoconazole as a first-line treatment, and verapanib as a second-line treatment. Verapanib can contribute to a fall in blood pressure.

My patient’s report shows repair-resistance is HSP27 -10%, HSP72 -15%, HSP90 normal and sensitivity to hyperthermia. How should I interpret this?

If the detected level of heat shock protein (HSP) is above zero (normal), this shows resistance to hyperthermia or radiation. If HSP is less than zero, this shows sensitivity to hyperthermia or radiation.

How reliable is a negative circulating tumour cell test result for pancreatic adenocarcinoma patients who have no metastasis after surgery?

RGCC’s circulating tumour cell test has a negative predictive value of about 86%. This means our test will correctly return a true negative result 86% of the time.

I only have a blood sample. Is it still possible to have a test that requires both blood and tissue samples?

This depends on the cancer. With the exception of the Oncotrace test, every RGCC test can be conducted with blood sample. Certain cancers, for example, glioblastoma and other types of brain cancer, require both a blood and a tissue sample for tests.

Is a sample in formalin suitable for molecular experiments?

Once tissue is placed in formalin the cells in the tissue are no longer viable. In order to maintain viable cells, you should place the tissue in the appropriate tissue vial provided by RGCC.

It is possible to isolate DNA and/or RNA from samples, if they can be fixed and a paraffin block can be produced (FFPE tissue). Therefore only DNA/RNA tests (ChemoSnip, CGH, Gene expression-RT PCR) can be performed on these samples.

Am I able to send samples of specialised formulations and products for testing? Will they be tested in combination in patients on multiple treatments?

You are welcome to send us any substance for testing. We can also offer combination tests, provided a doctor specifies the ratio of each component in the combination.

How many types of cancer are being tested in RGCC’s “all types of cancer” tests?

These tests are for all solid and blood tumours malignancies, with the exception of primary tumours of the central nervous system.

Which tests can I use to diagnose and follow up men with an enlarged prostate who cannot have a biopsy?

We would recommend the Oncotrace test for diagnostic guidance, and the Prostate Oncotrail test for follow up focused on prostate-specific membrane antigen (PSMA) and prostate-specific antigen (PSA) markers.

Didn’t get an answer to your query? Get in touch with your local RGCC office

Get in touch

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more